Quarterly ResultMay 7, 2026, 04:09 PM
Neumora Q1 Net Loss Narrows to $53.5M; Operating Expenses Down 25.5%
AI Summary
Neumora Therapeutics reported a reduced net loss of $53.5 million for Q1 2026, an improvement from $68.0 million in Q1 2025. The clinical-stage biopharmaceutical company also saw a significant decrease in total operating expenses by 25.5% to $52.9 million. As of March 31, 2026, cash and cash equivalents stood at $147.1 million, with the company continuing to incur losses and expecting to raise additional capital to fund its operations and pipeline development.
Key Highlights
- Net loss for Q1 2026 narrowed to $53.5 million, down 21.4% from $68.0 million in Q1 2025.
- Net loss per share improved to $(0.30) in Q1 2026 from $(0.42) in Q1 2025.
- Total operating expenses decreased 25.5% to $52.9 million in Q1 2026.
- Research and development expenses fell 26.0% to $38.6 million.
- General and administrative expenses decreased 24.1% to $14.3 million.
- Cash and cash equivalents were $147.1 million as of March 31, 2026.
- Net cash used in operating activities was $46.4 million, an improvement of 21.9%.
- Issued $10.9 million in common stock through at-the-market transactions in Q1 2026.
- Converted $2.05 million of term loan principal into common stock in February 2026.
Price Impact
More from NMRA